JAMA SJR and Scopus Metrics: What They Actually Mean
JAMA still has elite general-medicine metrics, but the real submission question is whether your paper belongs in a broad clinical flagship.
Next step
Choose the next useful decision step first.
Use the guide or checklist that matches this page's intent before you ask for a manuscript-level diagnostic.
JAMA at a glance
Key metrics to place the journal before deciding whether it fits your manuscript and career goals.
What makes this journal worth targeting
- IF 55.0 puts JAMA in a visible tier — citations from papers here carry real weight.
- Scope specificity matters more than impact factor for most manuscript decisions.
- Acceptance rate of ~<5% means fit determines most outcomes.
When to look elsewhere
- When your paper sits at the edge of the journal's stated scope — borderline fit rarely improves after submission.
- If timeline matters: JAMA takes ~2-3 weeks. A faster-turnaround journal may suit a grant or job deadline better.
- If open access is required by your funder, verify the journal's OA agreements before submitting.
Quick answer: JAMA still has elite Scopus standing in general medicine. Current Scopus-based sources place it at SJR 5.352, impact score 6.96, global rank 267, and h-index 794 in 2024. That confirms real flagship status, even if it sits below NEJM and The Lancet on pure prestige concentration. The useful submission question is whether the manuscript is broad and clinically important enough for a general-medical audience, not whether JAMA remains strong.
Direct answer
If your question is whether JAMA still behaves like a major general-medicine flagship in the Scopus system, the answer is yes.
Metric | Current value | What it tells you |
|---|---|---|
SJR | 5.352 | prestige-weighted influence remains elite in medicine |
Impact Score | 6.96 | citation density is still strong in current Scopus data |
Global rank | 267 | the journal remains near the top of the full ranking |
h-index | 794 | the archive is one of the deepest in clinical medicine |
Best quartile | Q1 | the title remains firmly top-tier |
Coverage history | 1883-2025 | this is durable flagship authority |
That profile matters because JAMA is still one of the central rooms for general-medical work that reaches clinicians across specialties.
Overview
The useful summary is that JAMA remains an elite general-medicine journal, but the 2024 profile is below the post-pandemic spike years. That does not make the journal soft. It just gives you a more honest baseline than the inflated 2021-2022 period.
For the broader fit picture, see our JAMA journal profile.
What changed in 2024
The 2024 picture is softer than 2023.
- SJR moved down from 5.928 in 2023 to 5.352 in 2024
- impact score moved down from 7.80 to 6.96
- global rank moved from 211 to 267
That matters because it confirms some normalization, not a change in journal identity. JAMA still has elite reach. It is just not sitting at the hottest point of the recent cycle.
Ten-year SJR and Scopus trend
Year | SJR | Impact Score | Global Rank |
|---|---|---|---|
2024 | 5.352 | 6.96 | 267 |
2023 | 5.928 | 7.80 | 211 |
2022 | 6.695 | 13.62 | 154 |
2021 | 6.076 | 15.13 | 188 |
2020 | 4.688 | 5.91 | 313 |
2019 | 5.913 | 5.79 | 212 |
2018 | 7.477 | 7.75 | 139 |
2017 | 8.876 | 7.99 | 100 |
2016 | 7.278 | 7.41 | 152 |
2015 | 6.892 | 7.03 | 161 |
2014 | 6.421 | 7.41 | 186 |
The trend shows a journal that remains elite across a decade even though the current numbers are not at the peak. That is the important planning signal for authors.
What the trend means in practice
For authors, the trend usually means:
- the journal still delivers broad clinical visibility
- strong specialty work can still be the wrong fit
- papers need importance beyond one clinical niche
- normalization in the metrics does not make the editorial screen much easier
That is why very good papers still get rejected here. The comparison set remains unusually strong.
How JAMA compares with realistic neighbors
Journal | Relative 2024 profile | What the metric profile usually signals |
|---|---|---|
JAMA | SJR 5.352 | elite general-medicine flagship below the top two leaders |
NEJM | materially stronger prestige concentration | best fit for the most practice-changing broad clinical studies |
The Lancet | materially stronger prestige concentration | strongest when the paper has very broad policy or global-health consequence |
The BMJ | lower prestige concentration but still major reach | good fit for broader evidence, policy, and practice-facing work |
This is the useful comparison. JAMA is not a specialty journal with good branding. It is a real general-medical flagship with a distinct place in the top tier.
What editors are really screening for
The current author guidance is clear enough to be useful:
- JAMA handles more than 11,500 annual submissions
- the overall acceptance rate is about 10%
- the research-manuscript acceptance rate is about 4%
- papers declined by JAMA may be referred within the JAMA Network
That is the right information gain signal for authors. The journal is highly selective, but it is selecting for broad general-medical consequence, not just raw citation upside.
In Our Pre-Submission Review Work on JAMA Metric Questions
In our pre-submission review work on JAMA metric questions, three mistakes recur.
The specialty-upgrade mistake. Authors often submit a strong specialty paper because it feels too broad for a subfield journal, even though it still does not read like general medicine.
The importance-framing mistake. Another common miss is clinical relevance that is real but not framed in a way that matters outside the immediate specialty.
The flagship-substitution mistake. We also see teams use JAMA's status as a reason to try it first without pressure-testing whether the paper truly belongs in a cross-specialty room. The SJR confirms the upside. It does not rescue the wrong audience fit.
That is the practical meaning of the metrics. JAMA remains strong because it keeps filtering for papers with unusually broad clinical consequence.
What these metrics mean for authors
For authors, the current profile says:
- publication here still carries substantial general-medical visibility
- the archive is deep enough that comparison pressure remains severe
- broad clinical consequence matters more than specialty excellence alone
- the metric profile supports ambition, but only if the manuscript shape is right
The h-index of 794 matters because it reflects a very deep archive of widely used general-medical content. A paper that lands here enters a demanding comparison set.
Submit If / Think Twice If
Submit if:
- the study clearly matters across specialties
- the manuscript can be understood and valued by a general-medical audience
- the clinical consequence is hard to miss
- the paper would still feel important outside the immediate subfield
Think twice if:
- the value depends heavily on specialist background
- the likely readership is still mostly one discipline
- the manuscript is excellent but not obviously general medicine
- the submission logic is being driven mostly by the brand
Readiness check
Run the scan while the topic is in front of you.
See score, top issues, and journal-fit signals before you submit.
What should drive the decision after the metrics check
The better question is whether the manuscript is truly a JAMA paper in its current form.
That is why the next useful reads are:
If the study is broad enough, the upside is real. If it is still mainly specialty-facing, the metric profile is mostly warning you that the mismatch will be expensive. A JAMA submission framing check is the fastest way to pressure-test that before submission.
Practical verdict
JAMA still has elite Scopus metrics and remains one of the most important general-medical journals in the world. The 2024 profile is softer than the recent peak, but not in a way that changes the core submission logic.
For authors, the metric question is already answered. The live question is whether the manuscript belongs in a broad clinical flagship.
Frequently asked questions
JAMA's 2024 SJR is 5.352 on current Scopus-based metric aggregators, which keeps it in the elite general-medicine tier.
Current Scopus-based sources place JAMA's 2024 impact score at 6.96, with a global rank of 267 and h-index of 794.
Because JAMA remains one of the central general-medical journals for broadly important clinical studies, policy-relevant research, and work that travels beyond one specialty.
No. The real question is whether the manuscript is broad, clinically important, and general enough for a top general-medicine audience.
Sources
- 1. JAMA metrics page, Resurchify.
- 2. JAMA for authors, JAMA Network.
- 3. JAMA journal homepage, JAMA Network.
Before you upload
Choose the next useful decision step first.
Move from this article into the next decision-support step. The scan works best once the journal and submission plan are clearer.
Use the scan once the manuscript and target journal are concrete enough to evaluate.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Start here
Same journal, next question
Supporting reads
Conversion step
Choose the next useful decision step first.
Use the scan once the manuscript and target journal are concrete enough to evaluate.